News

1 2 3 4 5 6
NEWS

Data from SOTIO’s Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors

  • Data demonstrate that SOT101 monotherapy and SOT101 in combination with pembrolizumab have a favorable safety profile;
  • Encouraging efficacy signals were observed for both SOT101 monotherapy and SOT101 in combination with pembrolizumab, even in patients with checkpoint-inhibitor relapsed and refractory tumors;
  • 15 out of 19 patients receiving SOT101 in combination with pembrolizumab had observed clinical benefit across all dose-levels;
  • Updated results will be presented as an oral presentation at this year’s ASCO meeting by Dr. Elena Garralda from the Vall D’Hebron Institute of Oncology, Barcelona, Spain;
  • AURELIO-04, a global Phase 2 study trial of SOT101 in combination with pembrolizumab in six distinct tumor types is expected to start in the coming weeks.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announces updated interim safety and efficacy data from its Phase 1/1b AURELIO-03 dose escalation study of the IL-2/IL-15 receptor βγ superagonist, SOT101, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. Data from the study show that SOT101 has a favorable safety profile. The recommended Phase 2 dose was defined at 12 µg/kg SOT101.

NEWS

Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual Meeting

  • SOTIO will share interim safety and efficacy results from SOTIO’s AURELIO-03 study on Saturday, June 4
  • AURELIO-03 is a Phase 1/1b dose escalation study of the interleukin-15 superagonist SOT101 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will deliver an oral presentation featuring interim safety and efficacy data from the Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, as monotherapy and in combination with pembrolizumab at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2022, taking place in Chicago, Illinois from June 3-7, 2022.

NEWS

Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting

  • Interim Results of the Phase 1 AURELIO-03 study of SOT101 in combination with pembrolizumab for patients with advanced metastatic tumors were presented at the 2022 AACR Annual Meeting
  • Data demonstrates that SOT101 in combination with pembrolizumab was well tolerated and the majority of patients had clinical benefit
  • Additional posters outline preclinical findings on immunocytokine, SOT201, and lead BOXR CAR-T platform candidate, BOXR1030

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced interim safety and efficacy results from the ongoing Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, in combination with pembrolizumab in patients with advanced/metastatic solid tumors. The data were presented by Dr. Stephane Champiat from Gustave Roussy Cancer Center in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022. The company also presented findings from preclinical studies of its immunocytokine candidate SOT201, and of its CAR-T cancer therapy BOXR1030 in two poster presentations at the meeting.